Objective Romiplostim, a second‑generation thrombopoietin receptor agonist (TPO‑RA), has been increasingly investigated for aplastic anemia (AA) across various populations and treatment settings; however, its overall efficacy, optimal dose, safety profile, and sources of heterogeneity across studies have not been systematically quantified and validated. This study aims to perform an up‑to‑date systematic review and single‑arm meta‑analysis to comprehensively assess the overall efficacy and safety of romiplostim in AA patients.
Methods We systematically searched PubMed, Embase, Web of Science, Cochrane Library, and CNKI from inception to March 3, 2026, without language restrictions. Two independent reviewers screened literature, extracted data, and assessed methodological quality using the Newcastle–Ottawa Scale (NOS) and Methodological Index for Non-Randomized Studies (MINORS). A random-effects model was applied in Stata 15.1 to pool overall response rate (ORR) and complete response rate (CRR); subgroup, sensitivity, and publication bias analyses were performed to explore heterogeneity and robustness.
Results Nineteen studies with 382 patients were included. The pooled ORR was 72.4% (95% CI: 61.9%–81.9%), and CRR was 25.5% (95% CI: 18.4%–33.1%). Patients receiving 20 μg/kg romiplostim achieved higher ORR (77.6% vs. 51.7%) and CRR (29.3% vs. 17.0%) than those receiving 10 μg/kg (P = 0.081). Patients aged <60 years showed higher ORR (74.9% vs. 49.3%) than those ≥60 years (P = 0.298). Tolerability was favorable, with low discontinuation rate (2.1%) and no treatment-related deaths.
Conclusion Romiplostim demonstrates promising efficacy and safety in AA, with enhanced outcomes at 20 μg/kg and in younger patients. Further high-quality trials are warranted.
| [1] |
Young NS. Aplastic Anemia. N Engl J Med., 2018, 379(17): 1643-1656.
|
| [2] |
Montané E, Ibáñez L, Vidal X, et al.. Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica., 2008, 93(4): 518-523.
|
| [3] |
Vaht K, Göransson M, Carlson K, et al.. Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000–2011. Haematologica., 2017, 102(10): 1683-1690.
|
| [4] |
Gale RP, Hinterberger W, Young NS, Gennery AR, Dvorak CC, Hebert KM, et al.. What causes aplastic anaemia?. Leukemia., 2023, 37(6): 1191-1193.
|
| [5] |
Shin SH, Lee JW. The optimal immunosuppressive therapy for aplastic anemia. Int J Hematol., 2013, 97(5): 564-572.
|
| [6] |
Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med. 1991;324(19):1297–1304.
|
| [7] |
Peslak SA, Olson T, Babushok DV. Diagnosis and Treatment of Aplastic Anemia. Curr Treat Options Oncol., 2017, 18(12): 70.
|
| [8] |
Desmond R, Townsley DM, Dumitriu B, et al.. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood., 2014, 123(12): 1818-1825.
|
| [9] |
Townsley DM, Scheinberg P, Winkler T, et al.. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. N Engl J Med., 2017, 376(16): 1540-1550.
|
| [10] |
Bussel JB, Soff G, Balduzzi A, et al.. A Review of Romiplostim Mechanism of Action and Clinical Applicability. Drug Des Devel Ther., 2021, 15: 2243-2268.
|
| [11] |
Akahori H, Shibuya K, Ozai M, et al.. Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice. Stem Cells., 1996, 14(6): 678-689.
|
| [12] |
Kaushansky K, Lin N, Grossmann A, et al.. Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice. Exp Hematol., 1996, 24(2): 265-269
|
| [13] |
Kovtonyuk LV, Manz MG, Takizawa H. Enhanced thrombopoietin but not G-CSF receptor stimulation induces self-renewing hematopoietic stem cell divisions in vivo. Blood., 2016, 127(25): 3175-3179.
|
| [14] |
Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest., 2005, 115(12): 3339-3347.
|
| [15] |
de Laval B, Pawlikowska P, Petit-Cocault L, et al.. Thrombopoietin-increased DNA-PK-dependent DNA repair limits hematopoietic stem and progenitor cell mutagenesis in response to DNA damage. Cell Stem Cell., 2013, 12(1): 37-48.
|
| [16] |
Guenther KL, Cheruku PS, Cash A, et al. Eltrombopag promotes DNA repair in human hematopoietic stem and progenitor cells. Exp Hematol. 2019;73:1–6.e.
|
| [17] |
Lee JW, Lee SE, Jung CW, et al.. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial. Lancet Haematol., 2019, 6(11): e562-e572.
|
| [18] |
Bordbar M, Faghihi A, Zekavat OR, et al.. Safety and efficacy of romiplostim in children with acquired aplastic anemia who are naive to immunosuppressive therapy. Haematologica., 2026, 111(3): 1061-1064
|
| [19] |
Dhingra G, Rajoreya A. A Single-Centre Experience of First-Line Romiplostim and Immunosuppressive Therapy in Patients With Aplastic Anemia. Cureus., 2023, 15(4): e37682
|
| [20] |
Hosokawa K, Yamazaki H, Tanabe M, et al.. High-dose romiplostim accelerates hematologic recovery in patients with aplastic anemia refractory to eltrombopag. HemaSphere., 2020, 4: 386
|
| [21] |
Ise M, Iizuka H, Kamoda Y, et al.. Romiplostim is effective for eltrombopag-refractory aplastic anemia: results of a retrospective study. Int J Hematol., 2020, 112(6): 787-794.
|
| [22] |
Jang JH, Tomiyama Y, Miyazaki K, et al.. Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study. Br J Haematol., 2021, 192(1): 190-199.
|
| [23] |
Lee JW, Jang JH, Chiba S, et al.. Romiplostim with ciclosporin A in patients with aplastic anaemia naïve to immunosuppressive therapy: A phase 2/3 study. Br J Haematol., 2025, 207(2): 582-590.
|
| [24] |
Lee JW, Jang JH, Yamazaki H, et al.. Addition of romiplostim to immunosuppressive therapy as first-line treatment for patients with aplastic anemia. Blood Adv., 2025, 9(22): 5732-5735.
|
| [25] |
Lin X, Yang C, Liu Z, et al.. Effective treatment of refractory aplastic anemia with romiplostim after failure of multiple thrombopoietin receptor agonists: a single-center retrospective study. Ann Med., 2025, 57(1): 2514791.
|
| [26] |
Madhupriya B, Ross C, Chaithanya HB, et al.. Efficacy of Romiplostim in Newly Diagnosed Aplastic Anaemia. Indian J Hematol Blood Transfus., 2024, 40: S6
|
| [27] |
Nadjat S. CT-023 Place of Romiplostim in the Treatment of Bone Marrow Aplasia—Experience of the Sidi Bel Abbès Hematology Department, Algeria. Clin Lymphoma Myeloma Leuk., 2024, 24(Suppl 1): S585.
|
| [28] |
Ramanan V, Kelkar K. Romiplostim in Aplastic Anemia: A Single-Center Retrospective Study. Cureus., 2025, 17(1): e78228
|
| [29] |
Sato S, Tsunoda S, Kamata W, et al.. Efficacy and safety of romiplostim in aplastic anemia refractory or intolerant to immunosuppressive therapy with eltrombopag. Jpn J Clin Hematol., 2025, 66(2): 92-99
|
| [30] |
Tak H, Trivedi M, Joshi N, et al.. Romiplostim and immunosuppressive therapy as first line treatment in patients with aplastic anemia. Pediatr Hematol Oncol J., 2023, 8(4): S64.
|
| [31] |
Wang T, Li L, Wang H, et al.. Efficacy and safety of romiplostim N01 combined with cyclosporine in refractory aplastic anemia patients:a multicenter phase II study. Blood., 2025, 146: 3195.
|
| [32] |
Zhang L, Ren X, Hu X, et al.. First-line romiplostim combined with immunosuppressive therapy for severe aplastic anemia: A prospective, single-arm. Phase II study. Blood., 2025, 146: 1426
|
| [33] |
Zhuang Q, Liu Z, Yang C, et al.. Efficacy and safety of romiplostim N01 for refractory aplastic anemia: A retrospective single-center study. Zhonghua Xue Ye Xue Za Zhi (Chinese)., 2026, 47(2): 177-181
|
| [34] |
Zhao LP, Sicre De Fontbrune F, Contejean A, et al. Nationwide survey in France on the use of romiplostim in patients with refractory severe aplastic anemia. Bone Marrow Transplant. 2019;54(7):1161–1163.
|
| [35] |
Sharathkumar A, Carr J, Claassen D, et al.. Romiplostim for Treatment of Children and Young Adults With Severe Aplastic Anemia and Myelodysplastic Syndrome. J Pediatr Hematol Oncol., 2024, 46(5): 252-261.
|
| [36] |
Nakao S. Romiplostim for aplastic anemia: beyond an eltrombopag alternative. Haematologica., 2026, 111(3): 794-796
|
| [37] |
Bell A, Fairbrother M, Jones K. Fixed and random effects models: making an informed choice. Qual Quant., 2019, 53(2): 1051-1074.
|
| [38] |
Kim JA, Shim JS, Lee GY, et al.. Microenvironmental remodeling as a parameter and prognostic factor of heterogeneous leukemogenesis in acute myelogenous leukemia. Cancer Res., 2015, 75(11): 2222-2231.
|
| [39] |
Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther., 2004, 76(6): 628-638.
|
| [40] |
Wang YM, Krzyzanski W, Doshi S, et al.. Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects. Aaps j., 2010, 12(4): 729-740.
|
| [41] |
Winkler T, Cooper JN, Townsley DM, et al.. Eltrombopag for Refractory Severe Aplastic Anemia: Dosing Regimens, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling. Blood., 2017, 130: 777.
|
| [42] |
Di Buduo CA, Currao M, Pecci A, et al.. Revealing eltrombopag's promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation. Haematologica., 2016, 101(12): 1479-1488.
|
| [43] |
Raslova H, Vainchenker W, Plo I. Eltrombopag, a potent stimulator of megakaryopoiesis. Haematologica., 2016, 101(12): 1443-1445.
|
| [44] |
Zhao Z, Sun Q, Sokoll LJ, et al, Grasmeder S, et al. Eltrombopag mobilizes iron in patients with aplastic anemia. Blood. 2018;131(21):2399–2402.
|
| [45] |
Kao YR, Chen J, Narayanagari SR, et al. Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag. Sci Transl Med. 2018;10(458).
|
Funding
Fundamental Research Funds for the Central Universities(NO. 15882026XCZX012)
Education and Industry Collaboration in Joint Training Program(220601164154747)
RIGHTS & PERMISSIONS
The Author(s), under exclusive licence to the Huazhong University of Science and Technology
PDF
